Search results for "HIV"

showing 10 items of 1527 documents

Pandemic (H1N1) 2009 and HIV Co-infection

2010

To the Editor: We report a case of pandemic (H1N1) 2009 infection in a man with serologic evidence of HIV-1 infection. The clinical course was complicated by lung and brain involvement (respiratory failure and lethargy), severe leukopenia, and thrombocytopenia, but complications resolved after treatment with oseltamivir (150 mg 2×/d). In November 2009, a 47-year-old man who had received a diagnosis of hepatitis C infection 8 months earlier sought treatment at Ospedale Santa Maria Nuova, Reggio Emilia, Italy. He had a 3-day history of fever, dry cough, and drowsiness. Eight days before being admitted, the man had resided in the hospital’s inpatient detoxification unit, in which at least 10 i…

Microbiology (medical)medicine.medical_specialtyOseltamivirEpidemiologyEncephalopathyletterlcsh:Medicinelcsh:Infectious and parasitic diseasesLethargychemistry.chemical_compoundLeukocytopeniaInternal medicinePandemic (H1N1) 2009medicineSore throatlcsh:RC109-216Letters to the EditorLeukopeniabusiness.industrylcsh:Rvirus diseasesHepatitis Cencephalopathymedicine.diseaseInfectious DiseasesItalyRespiratory failurechemistryImmunologyHIV-1medicine.symptombusinessEmerging Infectious Diseases
researchProduct

Human Immunodeficiency Virus Infection and Diverse Physical Health Outcomes: An Umbrella Review of Meta-analyses of Observational Studies.

2019

Abstract Background Our aim was to assess both the credibility and strength of evidence arising from systematic reviews with meta-analyses of observational studies and physical health outcomes associated with human immunodeficiency virus (HIV) but not acquired immunodeficiency syndrome. Methods We performed an umbrella review of observational studies. Evidence was graded as convincing, highly suggestive, suggestive, weak, or nonsignificant. Results From 3413 studies returned, 20 were included, covering 55 health outcomes. Median number of participants was 18 743 (range 403–225 000 000). Overall, 45 (81.8%) of the 55 unique outcomes reported nominally significant summary results (P < .05). O…

Microbiology (medical)medicine.medical_specialtyPopulationcomorbidHIV InfectionsDisease03 medical and health sciencesPulmonary Disease Chronic Obstructive0302 clinical medicineAcquired immunodeficiency syndrome (AIDS)Meta-Analysis as TopicPre-EclampsiaPregnancyInternal medicineMedicineHumanshealth outcomes030212 general & internal medicineeducationArticles and CommentariesCOPDeducation.field_of_studyhuman immunodeficiency virusumbrella reviewbusiness.industryhuman immunodeficiency viruPublic healthIncidence (epidemiology)IncidenceAn Umbrella Review of Meta-analyses of Observational Studies.- Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2019 [Grabovac I. Veronese N. Stefanac S. Haider S. Jackson S. Koyanagi A. Meilinger M. Stubbs B. Firth J. Soysal P. et al. -Human Immunodeficiency Virus Infection and Diverse Physical Health Outcomes]HIVmedicine.diseaseComorbidityObservational Studies as TopicInfectious DiseasesCross-Sectional StudiesAcademicSubjects/MED00290health outcomeFemalebusiness030217 neurology & neurosurgeryCohort studySystematic Reviews as TopicClinical infectious diseases : an official publication of the Infectious Diseases Society of America
researchProduct

Body Mass Index and Weight Gain in Pregnant Women With HIV: A National Study in Italy.

2013

Although most of the women (69.4%) had a normal BMI at start of pregnancy, only 37% had an adequate weight gain during pregnancy. Inadequate body weight gain was more common (44.8%) than excessive weight gain (18.2%), but 40% of overweight women and 50% of obese women had an excessive weight gain in pregnancy, with about 9% of the women in these categories gaining >18 kg during pregnancy (Table 1). Only 1.9% of the women had a vaginal delivery; elective and nonelective cesarean deliveries accounted for 81.3% and 16.7% of deliveries, respectively. Compared to underweight/normal women, overweight/obese women had similar occurrences of preterm delivery (23.4% vs 22.7%, P = .871), significantly…

Microbiology (medical)medicine.medical_specialtyantiretroviral therapyMEDLINEHuman immunodeficiency virus (HIV)HIV Infectionsbody mass indexmedicine.disease_causeSettore MED/17 - MALATTIE INFETTIVEBody Mass IndexBMIBody Mass Index; weight gain; HIV-1; PregnancyPregnancyMedicineHumansHIV infection; pregnancy; body mass indexPregnancy Complications InfectiousPregnancybusiness.industryObstetricsCesarean SectionInfectiousPregnancy OutcomeHIVweight gainmedicine.diseaseHIV infectionPregnancy ComplicationsInfectious DiseasesItalyNational studyHIV-1Femalepregnancymedicine.symptombusinessWeight gainBody mass index
researchProduct

Le fonds d’archives de l’enquête sur Minot, Bourgogne

2014

International audience

Minot[SHS.INFO]Humanities and Social Sciences/Library and information sciences[ SHS ] Humanities and Social Sciences[ SHS.INFO ] Humanities and Social Sciences/Library and information sciences[SHS] Humanities and Social Sciences[SHS.INFO] Humanities and Social Sciences/Library and information sciencesComputingMilieux_MISCELLANEOUSarchives[SHS]Humanities and Social Sciences
researchProduct

Mitochondrial interference by anti-HIV drugs: mechanisms beyond Pol-γ inhibition.

2011

The combined pharmacological approach to the treatment of HIV infection, known as highly active antiretroviral therapy (HAART), has dramatically reduced AIDS-related morbidity and mortality. However, its use has been associated with serious adverse reactions, of which those resulting from mitochondrial dysfunction are particularly widespread. Nucleos(t)ide-reverse transcriptase inhibitors (NRTIs) have long been considered the main source of HAART-related mitochondrial toxicity due to their ability to inhibit Pol-γ, the DNA polymerase responsible for the synthesis of mitochondrial DNA. Nevertheless, accumulating evidence points to a more complex relationship between these organelles and NRTI…

Mitochondrial DNAMitochondrial DiseasesNucleic Acid Synthesis InhibitorDNA polymeraseAnti-HIV Agentsmedicine.medical_treatmentDNA-Directed DNA PolymeraseMitochondrionPharmacologyToxicologyAntiretroviral Therapy Highly ActivemedicineAnimalsHumansNucleic Acid Synthesis InhibitorsPharmacologyProteasebiologyvirus diseasesmedicine.diseaseReverse transcriptaseDNA Polymerase gammaMitochondriaMitochondrial toxicityToxicitybiology.proteinReverse Transcriptase InhibitorsTrends in pharmacological sciences
researchProduct

In Silico Insights into the SARS CoV-2 Main Protease Suggest NADH Endogenous Defences in the Control of the Pandemic Coronavirus Infection

2020

COVID-19 is a pandemic health emergency faced by the entire world. The clinical treatment of the severe acute respiratory syndrome (SARS) CoV-2 is currently based on the experimental administration of HIV antiviral drugs, such as lopinavir, ritonavir, and remdesivir (a nucleotide analogue used for Ebola infection). This work proposes a repurposing process using a database containing approximately 8000 known drugs in synergy structure- and ligand-based studies by means of the molecular docking and descriptor-based protocol. The proposed in silico findings identified new potential SARS CoV-2 main protease (MPRO) inhibitors that fit in the catalytic binding site of SARS CoV-2 MPRO. Several sel…

Models Molecular0301 basic medicineAgingmedicine.medical_treatmentcoronaviruslcsh:QR1-502Viral Nonstructural Proteinsmedicine.disease_causelcsh:Microbiology0302 clinical medicineSettore BIO/10 - BiochimicaCoronavirus 3C ProteasesCoronavirusvirus diseasesLopinavirHypothesisMolecular Docking SimulationCysteine EndopeptidasesDrug repositioningInfectious Diseases030220 oncology & carcinogenesisCoronavirus InfectionsOxidation-Reductionmedicine.drugDNA damageIn silicoPneumonia ViralBiologyAntiviral AgentsHIV-proteaseBetacoronavirus03 medical and health sciencesSARS-CoV-2 main proteaseVirologymedicineHumansComputer SimulationProtease InhibitorsPandemicsBinding SitesProteaseSARS-CoV-2Drug RepositioningCOVID-19HIV Protease InhibitorsDRUDIT web servicemolecular dockingNADbiology.organism_classificationVirologySettore CHIM/08 - Chimica FarmaceuticaCOVID-19 Drug Treatmentcoronaviru030104 developmental biologyNADHRitonavirBetacoronavirusDNA Damage
researchProduct

Role of HLA-B α-3 domain amino acid position 194 in HIV disease progression

2013

HLA class I molecules play a role in the regulation of innate immune response. Therefore, the interaction of HLA class I molecules with different activating and inhibitory receptors leads to balancing the immune response. Among the different family of receptors, NK receptors KIR3DL1/S1 and LIR1, play a major role. Aim of this study was to evaluate the role of amino acid polymorphic positions of HLA class I molecules interacting with NK receptors in HIV progression. In order to minimize the influence of viral variability, a cohort of children with a nosocomial monophyletic HIV-1 infection from the Benghazi Children Hospital has been evaluated. To assess the role of single amino acid position…

Models MolecularGene ExpressionKIR3DS1HIV InfectionsPeptide bindingLeukocyte Immunoglobulin-like Receptor B1ModelsImmunologicReceptorsInnateReceptors ImmunologicChildReceptorGeneticschemistry.chemical_classificationCross Infectioneducation.field_of_studyReceptors KIR3DL1Polymorphism Genetic; Models Molecular; Humans; Disease Progression; Gene Expression; HLA-B Antigens; Immunity Innate; Child; Receptors KIR3DL1; Protein Binding; HIV-1; Binding Sites; Receptors KIR3DS1; Receptors Immunologic; HIV Infections; Antigens CD; Protein Structure Tertiary; Signal Transduction; Amino Acid Substitution; Cross InfectionHLA-BCDAmino acidDisease ProgressionKIR3DL1Protein BindingSignal TransductionReceptors KIR3DS1Protein StructureImmunologyPopulationHuman leukocyte antigenBiologyGeneticKIR3DL1Antigens CDHumansPolymorphismAntigenseducationMolecular BiologySettore MED/04 - Patologia GeneralePolymorphism GeneticBinding SitesInnate immune systemImmunityMolecularImmunity InnateProtein Structure TertiaryAmino Acid SubstitutionchemistryHLA-B AntigensImmunologyHIV-1TertiaryMolecular Immunology
researchProduct

Molecular dynamics studies on HIV-1 protease: a comparison of the flap motions between wild type protease and the M46I/G51D double mutant

2007

The emergence of drug-resistant mutants of HIV-1 is a tragic effect associated with conventional long-treatment therapies against acquired immunodeficiency syndrome. These mutations frequently involve the aspartic protease encoded by the virus; knowledge of the molecular mechanisms underlying the conformational changes of HIV-1 protease mutants may be useful in developing more effective and longer lasting treatment regimes. The flap regions of the protease are the target of a particular type of mutations occurring far from the active site. These mutations modify the affinity for both substrate and ligands, thus conferring resistance. In this work, molecular dynamics simulations were perform…

Models MolecularGromacs 3.2Anti-HIV AgentsProtein Conformationmedicine.medical_treatmentflap motionMutantCatalysisVirusInorganic ChemistryProtein structureHIV ProteaseHIV-1 proteaseDrug Resistance ViralEnzyme StabilityHIV-1 proteasemedicineHumansComputer SimulationPhysical and Theoretical Chemistrychemistry.chemical_classificationProteasebiologyHIV-1 drug-resistant mutantOrganic ChemistryWild typeActive siteRecombinant ProteinsComputer Science ApplicationsCell biologyEnzymemolecular dynamics simulationAmino Acid SubstitutionComputational Theory and MathematicsBiochemistrychemistryMutationHIV-1biology.protein
researchProduct

Docking and multivariate methods to explore HIV-1 drug-resistance: a comparative analysis

2007

In this paper we describe a comparative analysis between multivariate and docking methods in the study of the drug resistance to the reverse transcriptase and the protease inhibitors. In our early papers we developed a simple but efficient method to evaluate the features of compounds that are less likely to trigger resistance or are effective against mutant HIV strains, using the multivariate statistical procedures PCA and DA. In the attempt to create a more solid background for the prediction of susceptibility or resistance, we carried out a comparative analysis between our previous multivariate approach and molecular docking study. The intent of this paper is not only to find further supp…

Models MolecularMultivariate statisticsMultivariate analysisAnti-HIV AgentsCombined useHuman immunodeficiency virus (HIV)Computational biologyDrug resistanceBiologyLigandsBioinformaticsmedicine.disease_causeHIV ProteaseMolecular descriptorDrug Resistance ViralDrug DiscoverymedicineHumansDOCKINGPhysical and Theoretical ChemistryBinding SitesHIV Protease InhibitorsSettore CHIM/08 - Chimica FarmaceuticaHIV Reverse TranscriptaseComputer Science ApplicationsDRUG RESISTANCEDocking (molecular)Drug DesignMultivariate AnalysisMutationHIV-1Computer-Aided DesignReverse Transcriptase InhibitorsMultivariate statisticalJournal of Computer-Aided Molecular Design
researchProduct

Antigen processing influences HIV-specific cytotoxic T lymphocyte immunodominance

2016

Udgivelsesdato: 2009-May-03 Although cytotoxic T lymphocytes (CTLs) in people infected with human immunodeficiency virus type 1 can potentially target multiple virus epitopes, the same few are recognized repeatedly. We show here that CTL immunodominance in regions of the human immunodeficiency virus type 1 group-associated antigen proteins p17 and p24 correlated with epitope abundance, which was strongly influenced by proteasomal digestion profiles, affinity for the transporter protein TAP, and trimming mediated by the endoplasmatic reticulum aminopeptidase ERAAP, and was moderately influenced by HLA affinity. Structural and functional analyses demonstrated that proteasomal cleavage 'prefer…

Models MolecularProteasome Endopeptidase ComplexHIV AntigensMolecular Sequence DataImmunologyAntigen presentationHIV Core Protein p24HIV InfectionsImmunodominanceMajor histocompatibility complexgag Gene Products Human Immunodeficiency VirusEpitopeEvolution MolecularMajor Histocompatibility ComplexLeucyl Aminopeptidase03 medical and health sciences0302 clinical medicineAntigenHumansImmunology and AllergyCytotoxic T cellAmino Acid Sequence030304 developmental biologyAntigen Presentation0303 health sciencesHLA-A AntigensbiologyImmunodominant EpitopesAntigen processingVirology3. Good healthCTL*MutationHIV-1biology.proteinATP-Binding Cassette TransportersProtein BindingT-Lymphocytes Cytotoxic030215 immunologyRETROVIROLOGY
researchProduct